Wednesday, July 8, 2026

biotech · Melanoma · Previously untreated, unresectable, or metastatic melanoma · IOBTQ

IO Biotech

IO Biotech is a biotech organization headquartered in copenhagen, DK. It trades on NYSE under ticker IOBTQ. Primary therapeutic focus areas include Melanoma, Previously untreated, unresectable, or metastatic melanoma, ad

Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK HQ
2015 Founded
50 Employees
Public company Type
IOBTQ · NYSE Ticker
Company details
Status
Public
HQ
Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK
Founded
2015
Employees
50
Programs
16
Drugs
8
Patents
21
Clinical program

IO102-IO103

Phase 2 · small molecule · Melanoma

IO102-IO103 for Melanoma is a Phase 2 program (small_molecule) at IO Biotech with 2 ClinicalTrials.gov record(s).

← All IO Biotech projects Phase 2 small molecule active

Internal code IO102-IO103-032/IOB-032

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
IO Biotech
Phase
Phase 2
Modality
small_molecule
Indication
Melanoma
Status
active
Trials
2